Drug Information Association Logo

Rajiv Gulati to Speak at DIA India’s 6th Regulatory Conference

MUMBAI, INDIA — Mar 8, 2013

The President of the Global Pharmaceuticals Business at Ranbaxy Laboratories, Rajiv Gulati, will give a keynote speech on the theme ‘India, the Upcoming Economy: Encouraging Enforcement of Regulations’ at the 6th Regulatory Conference in India.

The two-day event, to be held in Ahmedabad, Gujarat from April 5-6, will bring together local and multinational pharmaceutical companies, clinical research professionals, academicians, regulators, and key stakeholders in health authorities to share the knowledge they’ve gained from decades of experience and note-worthy contributions to the development of the Indian pharmaceutical industry.

Other high-profile speakers will include K. Anand, president of global quality and regulatory affairs at Zydus Cadila, and Rajiv Desai, president of quality at Dishman Pharmaceuticals and Chemicals Ltd. Also participating will be the Drug Controller General of India (DCGI), Dr. G. N. Singh, and Zoher Sihorwala, vice president global regulatory affairs, Dr Reddys Lab.

Program Cochair, Dr. Hemant Koshia, food and drug commissioner of Gujarat, said: “DIA India’s 6th Regulatory Conference will focus on the challenge of keeping the Indian pharmaceutical industry competitive in the world market despite ever-evolving regulation. Attendees will discuss current issues in the regulatory field, deliberate how to be prepared to face up to these complexities by learning from the past, and decide proactive measures that could be taken by the industry.”

Session highlights:

  • Regulatory in Aseptic Technologies
  • Quality by Design (QbD) Approaches in Drug Development
  • Anticipating Regulatory Deficiencies – Post Filing
  • Regulatory Pathway in Biosimilars
  • Role of Biological Assessment in Drug Discovery
  • ICH Q11 – Challenges in Implementation
  • Challenges in Harmonization in Quality/Regulatory System  in Indian Perspective
  • Laboratories Expectations in Regulatory Market Environment
  • Meeting Regulatory Expectations in Drug Devices Despite Formal Laid Down Regulatory Guidelines

To find out more about the event, or to register, visit www.diahome.org/India6thRegulatory.






ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.